You are here

KRAS

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer and MD Anderson extend KRAS cancer collaboration

Pharmaforum

Boehringer Ingelheim

Flag link:

Boehringer’s big cancer reveal draws near

Boehringer’s big cancer reveal draws near

EP Vantage

Boehringer Ingelheim

Flag link:

Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

Fierce Biotech

Mirati Therapeutics

Flag link:

Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib

Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib

Fierce Biotech

Flag link:

Amgen teases 'promising' phase 2 data for closely watched KRAS prospect

Amgen teases 'promising' phase 2 data for closely watched KRAS prospect

Fierce Biotech

clinical trials

non-small cell lung cancer

Flag link:

Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug

Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug

Fierce Biotech

clinical trials

Flag link:

Verastem pens KRAS-focused drug licensing deal with Chugai

Verastem pens KRAS-focused drug licensing deal with Chugai

Fierce Biotech

Flag link:

KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

Fierce Biotech

Flag link:

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

Fierce Biotech

Flag link:

Novartis sends second wagon after KRAS gold rush

Novartis sends second wagon after KRAS gold rush

Endpoints

Flag link:

Mirati sets date for closely watched clinical KRAS readout

Mirati sets date for closely watched clinical KRAS readout

Fierce Biotech

Mirati Therapeutics

Flag link:

As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans

As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans

Endpoints

Boehringer Ingelheim

Flag link:

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

Xconomy

PARP inhibitors

prostate cancer

Seattle Genetics

Flag link:

Colon cancer proves tougher target for Amgen's KRAS drug

Colon cancer proves tougher target for Amgen's KRAS drug

Biopharma Dive

Flag link:

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Xconomy

Blueprint Medicines

Flag link:

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

BioSpace

Mirati Therapeutics

Flag link:

3 takeaways from cancer's biggest conference

3 takeaways from cancer's biggest conference

Biopharma Dive

accelerated approvals

Turning Point Therapeutics

Flag link:

3 Cancer Stocks Given a Lift by Amgen

3 Cancer Stocks Given a Lift by Amgen

Motley Fool

Mirati Therapeutics

Array Biopharma

Gilead Sciences

Flag link:

Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Investors Business Daily

Flag link:

Early cancer drug data give Amgen hope it's 'cracked KRAS code'

Early cancer drug data give Amgen hope it's 'cracked KRAS code'

Biopharma Dive

colorectal cancer

pancreatic cancer

Flag link:

Pages